ADC Therapeutics to Participate in March Investor Conferences

Core Insights - ADC Therapeutics is participating in two investor conferences in March 2026, showcasing its commitment to engaging with investors and stakeholders [1] Group 1: Upcoming Conferences - ADC Therapeutics will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 11:50 a.m. EST, with CEO Ameet Mallik as the speaker [1] - The company will also participate in the Jefferies Biotech on the Beach Summit on March 11, 2026, focusing on one-on-one meetings [1] Group 2: Company Overview - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates (ADCs), with a focus on transforming treatment for patients [1] - The company's CD19-directed ADC, ZYNLONTA (loncastuximab tesirine-lpyl), has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [1] - ZYNLONTA is also being developed in combination with other agents and in earlier lines of therapy [1]